Registry for triple-negative breast cancer and inherited mutation carriers
Part of Cancer, Genetic & congenital, Hormones & metabolism, Skin, Women’s health & pregnancy clinical trials.
This registry studies people with triple-negative breast cancer or inherited “HBOC” gene mutations (like BRCA, PALB2, PTEN, TP53). It collects information to better understand risk, outcomes, and how these cancers behave—helping future research and care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have triple-negative breast cancer, or you carry an inherited HBOC gene mutation
- If you have triple-negative breast cancer, you must be within 5 years of your diagnosis
- Triple-negative means ER and PR are very low (less than 10%) and HER is negative on standard testing
- If you carry an HBOC mutation, it must be considered harmful or “uncertain,” not just a harmless DNA variation
- You may be any age, and the trial allows people with or without a personal history of cancer (for mutation carriers)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an observational study that looks at how different cancer prevention approaches affect women with harmful (deleterious) BRCA1 or BRCA2 mutations. It may help improve future prevention and follow-up plans for women at higher inherited risk.
This study helps people in Switzerland who already have a known inherited cancer gene change understand what it means for them and their family. It focuses on people with specific known mutations related to hereditary breast/ovarian cancer and Lynch syndrome.
This study examines how different molecular subtypes (patterns of genes and proteins) of breast cancer behave in people with BRCA1 or BRCA2 mutations. By studying tumor samples and medical records, researchers hope to better predict which treatments will work best and predict long-term outcomes for BRCA-positive breast cancer patients.
This study collects blood (and possibly tumor tissue) to learn how certain inherited gene changes relate to breast and ovarian cancer risk. It may help researchers understand which people are most likely to develop these cancers and how tumors differ in high-risk patients.
This registry collects information from pre- or perimenopausal women with early breast cancer who are treated with standard care, plus tumor testing like MammaPrint®. It may help doctors better understand which treatments work best for different risk groups.
This study helps identify people who may have an inherited cancer risk and checks how best to support them. Depending on the group, you may only fill out surveys, or you may also create an app account and possibly provide a DNA sample.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.